Understanding the Advances and Innovations in Diagnostics for Early Detection of Alzheimer's Disease.

Interview with a knowledgeable Alzheimer's Disease KOL and/or PI with in-depth knowledge of the current diagnostic strategies being undertaken by companies such as Eli Lilly, Biogen, and Eisai. Understand the expert-specific R&D activities that are planned or underway to address early Alzheimer’s diagnosis gaps across the clinical care pathway. This includes understanding early perceptions of emerging Alzheimer’s Disease diagnostic strategies, including Blood-based Biomarkers (BBB) and Elecsys Amyloid Plasma Panel (EAPP) programs.